• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13D/A filed by AdaptHealth Corp.

    3/12/26 9:10:34 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care
    Get the next $AHCO alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13D

    Under the Securities Exchange Act of 1934

    (Amendment No. 4)


    AdaptHealth Corp.

    (Name of Issuer)


    Common Stock, par value $0.0001 per share

    (Title of Class of Securities)




    Gregory Belinfanti
    c/o One Equity Partners, 510 Madison Avenue, 19th Floor
    New York, NY, 10022
    (212) 277-1500


    Jeremy S. Liss
    c/o Kirkland & Ellis LLP, 98 S.E. 7th Street, Suite 700
    Miami, FL, 33131
    (305) 432-5600


    Ross M. Leff
    c/o Kirkland & Ellis LLP, 601 Lexington Avenue
    New York, NY, 10022
    (212) 446-4800


    Jeremy S. Liss
    c/o Kirkland & Ellis LLP, 333 West Wolf Point Plaza
    Chicago, IL, 60654
    (312) 862-2000

    (Name, Address and Telephone Number of Person Authorized to Receive Notices and Communications)
    03/10/2026

    (Date of Event Which Requires Filing of This Statement)


    If the filing person has previously filed a statement on Schedule 13G to report the acquisition that is the subject of this Schedule 13D, and is filing this schedule because of §§ 240.13d-1(e), 240.13d-1(f) or 240.13d-1(g), check the following box. Checkbox not checked

    The information required on the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provisions of the Act (however, see the Notes).






    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    OEP AHCO Investment Holdings, LLC
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,864,871.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,864,871.00
    11Aggregate amount beneficially owned by each reporting person

    15,864,871.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.7 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    The reported percentage is calculated based on 135,914,816 shares of Common Stock, par value $0.0001 per share ("Common Stock") outstanding as of February 20, 2026, as reported in the Issuer's Annual Report on Form 10-K ("Form 10-K") filed with the SEC on February 24, 2026.


    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    One Equity Partners VII, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,864,871.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,864,871.00
    11Aggregate amount beneficially owned by each reporting person

    15,864,871.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.7 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026.


    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    One Equity Partners VII-A, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,864,871.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,864,871.00
    11Aggregate amount beneficially owned by each reporting person

    15,864,871.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.7 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026.


    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    One Equity Partners VII-B, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,864,871.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,864,871.00
    11Aggregate amount beneficially owned by each reporting person

    15,864,871.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.7 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026.


    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    OEP VII Project A Co-Investment Partners, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,864,871.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,864,871.00
    11Aggregate amount beneficially owned by each reporting person

    15,864,871.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.7 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026.


    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    OEP VII Project A-I Co-Investment Partners, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    OO
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,864,871.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,864,871.00
    11Aggregate amount beneficially owned by each reporting person

    15,864,871.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.7 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026.


    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    OEP VII General Partner, L.P.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,864,871.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,864,871.00
    11Aggregate amount beneficially owned by each reporting person

    15,864,871.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.7 %
    14Type of Reporting Person (See Instructions)

    PN

    Comment for Type of Reporting Person:
    The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026.


    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    OEP VII GP, L.L.C.
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    CAYMAN ISLANDS
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,864,871.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,864,871.00
    11Aggregate amount beneficially owned by each reporting person

    15,864,871.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.7 %
    14Type of Reporting Person (See Instructions)

    OO

    Comment for Type of Reporting Person:
    The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026.


    SCHEDULE 13D

    CUSIP Number(s):


    1 Name of reporting person

    Richard Cashin
    2Check the appropriate box if a member of a Group (See Instructions)

    Checkbox not checked  (a)
    Checkbox checked  (b)
    3SEC use only
    4 Source of funds (See Instructions)

    AF
    5 Check if disclosure of legal proceedings is required pursuant to Items 2(d) or 2(e)

    Checkbox not checked
    6Citizenship or place of organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    7Sole Voting Power

    0.00
    8Shared Voting Power

    15,864,871.00
    9Sole Dispositive Power

    0.00
    10Shared Dispositive Power

    15,864,871.00
    11Aggregate amount beneficially owned by each reporting person

    15,864,871.00
    12Check if the aggregate amount in Row (11) excludes certain shares (See Instructions)

    Checkbox not checked
    13Percent of class represented by amount in Row (11)

    11.7 %
    14Type of Reporting Person (See Instructions)

    IN

    Comment for Type of Reporting Person:
    The reported percentage is calculated based on 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026.


    SCHEDULE 13D

    Item 1.Security and Issuer
    (a)Title of Class of Securities:

    Common Stock, par value $0.0001 per share
    (b)Name of Issuer:

    AdaptHealth Corp.
    (c)Address of Issuer's Principal Executive Offices:

    555 EAST NORTH LANE, SUITE 5075, CONSHOHOCKEN, PENNSYLVANIA , 19428.
    Item 1 Comment:
    This Amendment No. 4 (this "Amendment") to Schedule 13D, which amends the Schedule 13D filed with the SEC on July 10, 2020 (the "Schedule 13D"), as amended by Amendment No. 1 (the "First Amendment") to Schedule 13D filed with the SEC on August 10, 2020, Amendment No. 2 (the "Second Amendment") to Schedule 13D filed with the SEC on August 24, 2020, and Amendment No. 3 (the "Third Amendment") to Schedule 13D filed with the SEC on August 31, 2020, is being filed by the Reporting Persons (as defined below) with respect to shares of Common Stock of the Issuer. Capitalized terms used herein but not defined have the meanings ascribed to them in the Schedule 13D, as amended by the First Amendment, Second Amendment, and Third Amendment.
    Item 2.Identity and Background
    (a)
    Item 2(a) of the Schedule 13D is hereby amended and restated as follows: This Amendment is filed jointly on behalf of the entities and persons described in this Item 2(a), all of whom are together referred to herein as the "Reporting Persons." (i) OEP AHCO Investment Holdings, LLC, a Delaware limited liability company ("Investor") (ii) One Equity Partners VII, L.P., a Cayman Islands exempted limited partnership ("OEP VII LP") (iii) One Equity Partners VII-A, L.P., a Cayman Islands exempted limited partnership ("OEP VII-A LP") (iv) One Equity Partners VII-B, L.P., a Delaware limited partnership ("OEP VII-B LP") (v) OEP VII Project A Co-Investment Partners, L.P., a Delaware limited partnership ("OEP VII Project A LP") (vi) OEP VII Project A-I Co-Investment Partners, L.P. , a Delaware limited partnership ("OEP VII Project A-I LP" and, together with OEP VII LP, OEP VII-A LP, OEP VII-B LP and OEP VII Project A LP, the "Parallel Funds") (vii) OEP VII General Partner, L.P., a Cayman Islands exempted limited partnership ("OEP VII GP") (viii) OEP VII GP, L.L.C., a Cayman Islands limited liability company ("OEP VII GP LLC") (ix) Richard Cashin
    Item 5.Interest in Securities of the Issuer
    (a)
    Item 5(a) of the Schedule 13D is hereby supplemented as follows: The information set forth in rows (11) and (13) of the cover pages of this Schedule 13D is incorporated by reference into this Item 5. Ownership percentages set forth in this Schedule 13D assume 135,914,816 shares of Common Stock outstanding as of February 20, 2026, as reported in the Issuer's Form 10-K filed with the SEC on February 24, 2026. As of the date hereof, each of the Reporting Persons may be deemed the beneficial owner of 15,864,871 shares of Common Stock, which represents approximately 11.7% of the total outstanding Common Stock. The reported securities are directly held by Investor. Investor is owned by the Parallel Funds. The general partner of each of the Parallel Funds is OEP VII GP, and the general partner of OEP VII GP is OEP VII GP LLC. The six member investment committee of OEP VII GP acts by majority vote, which majority must include Richard Cashin. Accordingly, Richard Cashin may be deemed to have voting and investment discretion, and beneficial ownership, of the reported securities. Neither the filing of this statement nor any of its contents shall be deemed to constitute an admission by any of the Reporting Persons that such person is the beneficial owner of any shares of Common Stock referred to herein for purposes of the Act, or for any other purpose.
    (b)
    Item 5(b) of the Schedule 13D is hereby supplemented as follows: The information set forth in rows (7) through (10) of the cover pages of this Schedule 13D is incorporated by reference into this Item 5.
    (c)
    Item 5(c) of the Schedule 13D is hereby supplemented as follows: Within the prior 60 days, the Reporting Persons acquired shares of Common Stock in the market transactions set forth in Exhibit 7 attached hereto.
    (d)
    Not applicable.
    (e)
    Not applicable.
    Item 7.Material to be Filed as Exhibits.
     
    Exhibit 1 of Item 7 of the Schedule 13D is hereby amended and restated and Item 7 is hereby supplemented as follows: Exhibit 1 Joint Filing Agreement, dated March 12, 2026. Exhibit 6 Signature Page, dated March 12, 2026. Exhibit 7 Transactions by the Reporting Persons.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    OEP AHCO Investment Holdings, LLC
     
    Signature:/s/ Gregory Belinfanti
    Name/Title:Gregory Belinfanti / Authorized Signatory
    Date:03/12/2026
     
    One Equity Partners VII, L.P.
     
    Signature:/s/ Gregory Belinfanti
    Name/Title:Gregory Belinfanti / Authorized Signatory, See Exhibit 6
    Date:03/12/2026
     
    One Equity Partners VII-A, L.P.
     
    Signature:/s/ Gregory Belinfanti
    Name/Title:Gregory Belinfanti / Authorized Signatory, See Exhibit 6
    Date:03/12/2026
     
    One Equity Partners VII-B, L.P.
     
    Signature:/s/ Gregory Belinfanti
    Name/Title:Gregory Belinfanti / Authorized Signatory, See Exhibit 6
    Date:03/12/2026
     
    OEP VII Project A Co-Investment Partners, L.P.
     
    Signature:/s/ Gregory Belinfanti
    Name/Title:Gregory Belinfanti / Authorized Signatory, See Exhibit 6
    Date:03/12/2026
     
    OEP VII Project A-I Co-Investment Partners, L.P.
     
    Signature:/s/ Gregory Belinfanti
    Name/Title:Gregory Belinfanti / Authorized Signatory, See Exhibit 6
    Date:03/12/2026
     
    OEP VII General Partner, L.P.
     
    Signature:/s/ Gregory Belinfanti
    Name/Title:Gregory Belinfanti / Authorized Signatory, See Exhibit 6
    Date:03/12/2026
     
    OEP VII GP, L.L.C.
     
    Signature:/s/ Gregory Belinfanti
    Name/Title:Gregory Belinfanti / Authorized Signatory
    Date:03/12/2026
     
    Richard Cashin
     
    Signature:/s/ Richard Cashin
    Name/Title:Richard Cashin
    Date:03/12/2026
    Get the next $AHCO alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $AHCO

    DatePrice TargetRatingAnalyst
    1/8/2024$14.50 → $8.00Buy → Hold
    Jefferies
    11/8/2023$9.50 → $6.50Neutral → Underperform
    BofA Securities
    5/10/2023$28.00 → $11.30Buy → Hold
    Deutsche Bank
    5/10/2023$18.00 → $11.00Buy → Hold
    Stifel
    5/9/2023$21.00 → $12.00Buy → Neutral
    BofA Securities
    3/8/2022$31.00 → $26.00Outperform
    RBC Capital
    3/2/2022$32.00 → $24.00Outperform
    SVB Leerink
    2/18/2022$35.00 → $32.00Outperform
    SVB Leerink
    More analyst ratings

    $AHCO
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    AdaptHealth Corp. to Participate in Upcoming Investor Conferences

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that they will participate in the following upcoming investor conferences: The J.P. Morgan Global Leveraged Finance Conference, being held in Miami, on Tuesday, March 3, 2026, including a fireside chat at 11:00 a.m. ET. The Leerink Partners Global Healthcare Conference, being held in Miami, on Monday, March 9, 2026, including a fireside chat at 2:20 p.m. ET. Webcast links will be available on the Company's website, www.adapthealth.com under "Investor R

    2/25/26 4:05:00 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2025 Results and Provides 2026 Financial Guidance

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter Business Highlights Set patient census records for Sleep Health, Respiratory Health, and Wellness at Home, and a patient retention record for Diabetes Health. Acquired a leading HME provider in Hawaii, expanding the Company's geographic footprint to its 48th State and establishing operations to support the Company's new key capitated contract. Made signif

    2/24/26 7:00:00 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    AdaptHealth Corp. Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its fourth quarter and full year 2025 financial results before the opening of the financial markets on Tuesday, February 24, 2026. Management will host a teleconference at 8:30 a.m. ET to discuss the results and business activities with analysts and investors. Interested parties may participate in the call by dialing: (833) 316-2483 (Domestic) or (785) 838-9284 (International) When prompted, reference Conference ID: AHCO4Q25 Webcast registration: Clic

    2/3/26 4:05:00 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cashin Richard M Jr bought $19,912,148 worth of shares (2,046,691 units at $9.73) (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/12/26 9:11:41 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/3/26 6:41:28 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    CLO and General Counsel Rew Richard W. Ii bought $44,550 worth of shares (5,000 units at $8.91), increasing direct ownership by 5% to 107,097 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    2/27/26 4:01:18 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Cashin Richard M Jr bought $19,912,148 worth of shares (2,046,691 units at $9.73) (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/12/26 9:11:41 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Director Weaver Susan T received a gift of 73,472 shares and gifted 73,472 shares, decreasing direct ownership by 77% to 21,346 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/9/26 9:14:51 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Director Wolf Dale B bought $71,680 worth of shares (8,000 units at $8.96), increasing direct ownership by 8% to 104,235 units (SEC Form 4)

    4 - AdaptHealth Corp. (0001725255) (Issuer)

    3/3/26 6:41:28 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13D/A filed by AdaptHealth Corp.

    SCHEDULE 13D/A - AdaptHealth Corp. (0001725255) (Subject)

    3/12/26 9:10:34 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    SEC Form 10-K filed by AdaptHealth Corp.

    10-K - AdaptHealth Corp. (0001725255) (Filer)

    2/24/26 5:09:46 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    AdaptHealth Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    8-K - AdaptHealth Corp. (0001725255) (Filer)

    2/24/26 7:11:54 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    AdaptHealth downgraded by Jefferies with a new price target

    Jefferies downgraded AdaptHealth from Buy to Hold and set a new price target of $8.00 from $14.50 previously

    1/8/24 9:03:40 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    AdaptHealth downgraded by BofA Securities with a new price target

    BofA Securities downgraded AdaptHealth from Neutral to Underperform and set a new price target of $6.50 from $9.50 previously

    11/8/23 6:22:25 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    AdaptHealth downgraded by Deutsche Bank with a new price target

    Deutsche Bank downgraded AdaptHealth from Buy to Hold and set a new price target of $11.30 from $28.00 previously

    5/10/23 6:33:54 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by AdaptHealth Corp.

    SC 13G/A - AdaptHealth Corp. (0001725255) (Subject)

    11/14/24 9:03:31 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    SEC Form SC 13G filed by AdaptHealth Corp.

    SC 13G - AdaptHealth Corp. (0001725255) (Subject)

    11/13/24 9:30:46 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Amendment: SEC Form SC 13G/A filed by AdaptHealth Corp.

    SC 13G/A - AdaptHealth Corp. (0001725255) (Subject)

    11/12/24 1:30:20 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    Financials

    Live finance-specific insights

    View All

    AdaptHealth Corp. Announces Fourth Quarter and Full-Year 2025 Results and Provides 2026 Financial Guidance

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the fourth quarter and fiscal year ended December 31, 2025. Fourth Quarter Business Highlights Set patient census records for Sleep Health, Respiratory Health, and Wellness at Home, and a patient retention record for Diabetes Health. Acquired a leading HME provider in Hawaii, expanding the Company's geographic footprint to its 48th State and establishing operations to support the Company's new key capitated contract. Made signif

    2/24/26 7:00:00 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    AdaptHealth Corp. Announces Fourth Quarter and Full Year 2025 Earnings Release Date and Conference Call

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, will release its fourth quarter and full year 2025 financial results before the opening of the financial markets on Tuesday, February 24, 2026. Management will host a teleconference at 8:30 a.m. ET to discuss the results and business activities with analysts and investors. Interested parties may participate in the call by dialing: (833) 316-2483 (Domestic) or (785) 838-9284 (International) When prompted, reference Conference ID: AHCO4Q25 Webcast registration: Clic

    2/3/26 4:05:00 PM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    AdaptHealth Corp. Announces Third Quarter 2025 Results

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today financial results for the third quarter ended September 30, 2025. Third Quarter Business Highlights Signed another new capitated agreement to be the exclusive HME provider for a payor serving approximately 170,000 members, and added infrastructure to support our previously announced capitated partnership with a major national healthcare system. Advanced digital patient engagement and expanded self-service capabilities, growing registered myApp users to 271

    11/4/25 7:00:00 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    $AHCO
    Leadership Updates

    Live Leadership Updates

    View All

    AdaptHealth Corp. Announces Appointment of Russell Schuster as Chief Commercial Officer

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, announced today that Russell Schuster has been appointed Chief Commercial Officer, effective December 2nd, 2024. In his new role, Mr. Schuster will oversee commercial strategy and revenue generation for the Company. He is a seasoned executive with more than 25 years of experience and a proven track record of growing large businesses. Most recently, Mr. Schuster served as President of Cardinal Health Canada, where he delivered meaningful performance improvement. Over eight ye

    12/3/24 8:00:00 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    AdaptHealth Appoints Diana Nole to Board of Directors

    AdaptHealth Corp. (NASDAQ:AHCO) ("AdaptHealth" or the "Company"), a national leader in providing patient-centered, healthcare-at-home solutions including home medical equipment, medical supplies, and related services, today announced the appointment of Diana Nole to the Board of Directors, effective October 16, 2024. "We are thrilled to welcome Diana to the AdaptHealth Board of Directors. Her extensive leadership experience in the healthcare technology sector caught our eye and we soon discovered that her decisive, resourceful leadership style and expertise in business transformation aligned perfectly with our current goals as an organization," said Dale Wolf, Chairman of the AdaptHealth B

    10/17/24 8:00:00 AM ET
    $AHCO
    Medical/Nursing Services
    Health Care

    Advantage Healthcare Holdings Appoints Dinak Nair as Chief Executive Officer

    Advantage Healthcare Holdings ("Advantage" or the "Company"), a regional leader in providing patient-centered healthcare through managing and operating Comprehensive Outpatient Rehabilitation Facilities and Sleep Centers, announced that its Board of Directors has named Dinak (Dino) Nair as its Chief Executive Officer. Mr. Nair assumed leadership of the Company from the prior CEO, Ryan Tong, on September 1, 2024. Mr. Nair brings over 20 years of business experience, with more than a decade as a mission-driven leader growing businesses in the healthcare market, especially in homecare, home medical equipment, diagnostic laboratory, and health system partnerships. Mr. Nair most recently served

    9/25/24 11:19:00 AM ET
    $AHCO
    $LH
    Medical/Nursing Services
    Health Care
    Medical Specialities